Group 1 - China Resources Pharmaceutical (03320) announced a collaboration to establish a fund with an expected scale of RMB 500 million [1] - The fund is anticipated to focus on high-growth investments in synthetic biology, innovative drugs, and biotechnology sectors [1] - The company plans to commit a total investment of up to RMB 123 million, representing approximately 24.6% of the total committed capital for the fund [1] Group 2 - The fund is expected not to be accounted as a subsidiary of the company after its establishment [1] - Shenzhen China Resources Capital is expected to be appointed as the fund manager [1]

Core Viewpoint - China Resources Pharmaceutical (03320) is collaborating with partners to establish a fund with an expected scale of RMB 500 million, focusing on high-growth investments in synthetic biology, innovative drugs, and biotechnology sectors [1] Company Summary - The company plans to commit a total investment of up to RMB 123 million, which represents approximately 24.6% of the total committed capital for the fund [1] - The fund is expected not to be accounted as a subsidiary of the company after its establishment [1] - Shenzhen China Resources Capital is anticipated to be appointed as the fund manager [1]

集团拟承诺出资总额预期为不高于人民币1.23亿元，约占基金承诺出资总额的24.6%。预期基金于成立 后将不会入账为公司附属公司。预期深圳华润资本将获委托为基金基金管理人。 格隆汇8月12日丨华润医药(03320.HK)公告，华润医药(汕头)、华润双鹤、双鹤(北京)、华润医药投资 (各自为公司附属公司)与汉威华酉汕头及其他有意合伙人就成立预期规模为人民币5亿元基金进行协 商。基金预期主要从事合成生物学、创新药物及生物技术领域的高增长企业投资。 ...

Industry Overview - The cholesterol-lowering drug industry is crucial for preventing and treating cardiovascular diseases, with a growing patient population due to aging and increasing rates of dyslipidemia [1][8] - The prevalence of dyslipidemia among the elderly is high, with 47% of individuals over 60 affected, while the rate among those aged 18 and above has risen from 18.6% in 2002 to 35.6% in 2023 [8][10] Market Development - The cholesterol-lowering drug market in China is projected to grow from CNY 252.94 billion in 2023 to CNY 265.95 billion in 2024, despite a slowdown due to national procurement policies [10][20] - Sales distribution shows that 57% of sales come from hospitals, while 43% are from retail markets [10] Drug Categories - Cholesterol-lowering drugs are categorized into statins, fibrates, niacin, bile acid sequestrants, PCSK9 inhibitors, and monoclonal antibodies targeting angiopoietin-like protein 3 [3][12] - Statins dominate the market with a 76.58% share, but innovative drugs like PCSK9 inhibitors are gaining traction [12][22] Competitive Landscape - The market is experiencing significant changes, with foreign companies like Pfizer and Sanofi leading the high-end market, while local firms like Yuyuan Health and Jingxin Pharmaceutical focus on mid to low-end markets [14][16] - Competition is shifting from price to efficacy, safety, and brand service, with an expected increase in market concentration through mergers and international collaborations [14][22] Company Highlights - Jingxin Pharmaceutical focuses on the development and sales of statins and is expanding into combination therapies and new drug targets [16] - Yuyuan Health has developed a PCSK9-targeting siRNA drug, YKYY015, which is in clinical trials and has received IND approval in the U.S. [18] - The revenue of Yuyuan Health is projected to decline by 9.9% in 2024, with cardiovascular drug sales down by 20.73% [18] Future Trends - The market for cholesterol-lowering drugs is expected to continue expanding due to an increasing patient population and unmet treatment needs, with projections indicating a compound annual growth rate above a certain percentage [20][21] - Innovation in drug development is on the rise, with companies investing in new targets like Lp(a) and PCSK9 inhibitors, enhancing treatment options for patients [21][22]